banner2

Getting started
HMBA Linker

HMBA Linker - China Manufacturers, Suppliers, Factory

HMBA Linker, , , ,. The product will supply to all over the world, such as Europe, America, Australia,, ,, .

Related Products

HMBA Linker CAS 3006-96-0 Factory Shanghai Ruifu Chemical Co., Ltd. www.ruifuchem.com — HMBA Linker CAS 3006-96-0 4-(Hydroxymethyl)benzoic Acid Purity >99.0% (HPLC)
Read More

Ac-HMBA-Linker CAS 15561-46-3 Shanghai Ruifu Chemical Co., Ltd. www.ruifuchem.com — Ac-HMBA-Linker CAS 15561-46-3 4-(Acetoxymethyl)benzoic Acid Purity >98.0% (HPLC)

2-Hydroxyterephthalic Acid CAS 636-94-2 Factory Shanghai Ruifu Chemical Co., Ltd. www.ruifuchem.com — 2-Hydroxyterephthalic Acid CAS 636-94-2 (H2BDC-OH) MOF Linkers Purity >98.0% (HPLC)

Ramage Linker CAS 212783-75-0 Factory Shanghai Ruifu Chemical Co., Ltd. www.ruifuchem.com — Ramage Linker CAS 212783-75-0 Fmoc-Suberol Purity >98.0% (HPLC)

Rink-Amide-LinkerFmoc-Linker CAS 126828-35-1 Factory Shanghai Ruifu Chemical Co., Ltd. www.ruifuchem.com — Rink-Amide-Linker/Fmoc-Linker CAS 126828-35-1 Purity >98.0% (HPLC)

HMP Linker CAS 68858-21-9 Factory Shanghai Ruifu Chemical Co., Ltd. www.ruifuchem.com — HMP Linker CAS 68858-21-9 4-(Hydroxymethyl)phenoxyacetic Acid Purity >98.0% (HPLC)

DHP Linker CAS 3749-36-8 Factory Shanghai Ruifu Chemical Co., Ltd. www.ruifuchem.com — DHP Linker CAS 3749-36-8 3,4-Dihydro-2H-Pyran-2-Methanol Purity >99.0% (GC) Factory

banner1

Top Selling Products

Related Blog
Reviews

Focus on Cross Border Integration of Biomedicine and Chemical Materials, October 15, 2021

Focus on Cross Border Integration of Biomedicine and Chemical Materials: New Opportunities, New Technologies and New Models This forum focuses on the interdisciplinary and cutting-edge technologies...
The “Summit on COVID-19 Diagnostics & Treatment”

The “Summit on COVID-19 Diagnostics & Treatment” September 27-29, 2021 at China International Exhibition Center (Tianzhu New Hall), Beijing. The outbreak of Corona Virus Disease 2019 (...
Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk Of Hospitalization Or Death By 89% In Interim Analysis Of Phase 2/3 EPIC-HR Study

Friday, November 05, 2021 – 06:45am PAXLOVID™ (PF-07321332; ritonavir) was found to reduce the risk of hospitalization or death by 89% compared to placebo in non-hospitalized high-risk adult...
Paxlovid: what we know about Pfizer's Covid-19 pill

Pfizer is seeking emergency use authorisation from the FDA for its novel Covid-19 antiviral pill Paxlovid. Share Article On the heels of Merck antiviral molnupiravir’s UK approval, Pfizer...
Method Of Analyzing Palladium Content In Palladium Catalysts

1. Abstract Enrichment palladium of palladium catalysts by pyrometallurgy, then dissolve the palladium in admixture acid, the liquid is analyzed by AAS. 2. Reagent 2.1 Hydrochloric acid(ρ1.19g/ml) ...
The third Guangdong-Hong Kong-Macao Greater Bay Area Pharmaceutical Innovation Technology and Market Access Summit forum November 19 to 21, 2021

The third Guangdong-Hong Kong-Macao Greater Bay Area Pharmaceutical Innovation Technology and Market Access Summit forum November 19 to 21, 2021 As the world’s second largest medical market, ...

2022.05.03 05:42:14
2022.01.18 05:45:14
2022.01.16 23:15:32
2021.11.24 14:44:17
2021.10.19 04:37:17
2021.10.16 10:52:45

related search